AU2008200611B2 — Methods of treating patients suffering from movement disorders
Assigned to Kyowa Kirin Co Ltd · Expires 2011-12-15 · 14y expired
What this patent protects
METHODS OF TREATING PATIENTS SUFFERING FROM MOVEMENT DISORDERS Abstract 5 The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2 receptor antagonist to a patient in need thereof. The present inv…
USPTO Abstract
METHODS OF TREATING PATIENTS SUFFERING FROM MOVEMENT DISORDERS Abstract 5 The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2 receptor antagonist to a patient in need thereof. The present invention also relates to methods of decreasing the adverse effect of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further relates to methods and compositions 1o for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2 receptor antagonises (i.e., L-DOPA sparing effect). The present invention further relates to methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2 receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT 15 inhibitor and/or a MAO inhibitor. The present invention further relates to methods of prolonging effective treatment of Parkinson's disease by administering an adenosine A2 receptor antagonist singly or together with a dopamine agonist, and/or a COMT inhibitor, and/or a MAO inhibitor without prior or subsequent administration of L-DOPA, delaying or removing on-set of L-DOPA motor complication.
Drugs covered by this patent
- Nourianz (ISTRADEFYLLINE) · Kyowa Kirin
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.